Not Yet Recruiting
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
NCT06954116
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China